ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
02 Jan 2024 05:00

HSCEI Index Rebalance Preview: Zhongsheng (881 HK) Should Go This Time

Zhongsheng's rank has dropped a lot and index deletion appears to be a certainty. China Unicom is a potential add. There is over 2.5x ADV to trade...

Logo
807 Views
Share
17 Dec 2023 10:10

A-H Premium Weekly (Dec 15th): CMB, China Tourism, Ping An Insurance, BYD

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, China Tourism, Ping An Insurance, BYD.

Logo
515 Views
Share
bullishCNOOC Ltd
10 Dec 2023 17:51

HK Connect SOUTHBOUND Flows (To 8Dec23); CNOOC & China Mobile Both Now To The Buy Side, Tencent Not

SOUTHBOUND flows were a strong HK$11.2bn net inflow, with both ETFs and high-div SOEs seeing big net inflows. Despite that, Hs underperformed their...

Logo
490 Views
Share
10 Dec 2023 10:10

A-H Premium Weekly (Dec 8th): CMB, Ping An Insurance, Beigene

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, Ping An Insurance and Beigene.

Logo
685 Views
Share
09 Dec 2023 10:23

[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

​China's drug sector is driven by liquidity, with limited investment choices. Akeso and BeiGene are recommended as buy options, while RemeGen,...

Share
x